Financial Estimates and Results - The company issued a press release on January 13, 2026, providing preliminary estimates for full-year 2025 revenue, net income, gross margin percentage, and adjusted EBITDA margin[4] - Preliminary estimates indicate that the company's cash and investments balance as of December 31, 2025, will be reported[4] - The financial statements for the year ended December 31, 2025, have not been finalized or audited, and actual results may differ materially from preliminary estimates[5] - PricewaterhouseCoopers LLP has not audited or reviewed the preliminary financial data provided by the company[7] - The preliminary financial data is the responsibility of the company's management and should not be relied upon without caution[5] - The company has not disclosed specific figures for revenue or net income in the provided documents[4] Conference Participation - Vericel Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. Pacific Time[4] Regulatory Information - The company is not classified as an emerging growth company under the Securities Act of 1933[3] - The information in this report is not deemed "filed" under the Securities Exchange Act of 1934[8] - The press release titled "Vericel Announces Preliminary 2025 Financial Results and Business Updates" is included as Exhibit 99.1[9]

Financial Results Presentation - Coherus Oncology, Inc. will present preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2025, at the 43rd Annual J.P. Morgan Healthcare Conference[4] - The financial closing procedures for the quarter and fiscal year ended December 31, 2025, are not yet complete, which may lead to significant changes in the preliminary results[6] - The independent registered public accounting firm has not reviewed or audited the financial results presented in this announcement[6] Forward-Looking Statements and Risks - Forward-looking statements include projected revenue growth for LOQTORZI, which involves substantial risks and uncertainties[7] - The company highlights risks related to market acceptance of its products by healthcare providers and patients, as well as potential litigation risks[7]

Financial Results - Treace Medical Concepts, Inc. reported preliminary unaudited financial results for the quarter and year ended December 31, 2025[5]. Upcoming Events - The company plans to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 am Pacific Time[7]. - The investor presentation will be available on the company's investor relations website, providing insights for analysts and investors[7].

Financial Performance - nLIGHT, Inc. announced preliminary results for Q4 2025, with actual results still being finalized, indicating potential discrepancies from management's expectations[5] - The earnings release was issued on January 13, 2026, detailing the company's financial performance for the fourth quarter ended December 31, 2025[7] - The report is subject to further review, and actual results could differ materially from the preliminary figures provided[5]

Financial Results - AudioEye, Inc. announced preliminary estimated unaudited financial results for Q4 2025 on January 13, 2026[6]. - The report is not deemed "filed" under the Securities Exchange Act of 1934, indicating it is preliminary information[7]. - The press release detailing financial results is attached as Exhibit 99.1[6]. Company Information - The company is listed on The Nasdaq Capital Market under the symbol AEYE[4]. - David Moradi serves as the Chief Executive Officer of AudioEye, Inc.[10].

Market Growth and Projections - Revenue for 2025 is projected to increase by 158% compared to 2024, with a preliminary estimate of $251 million[5]. - The global surgical robotics market is expected to grow at a CAGR of 14.7%, reaching approximately $27.1 billion by 2030[8]. - The surgical robotics market was valued at $851 million in 2023 and is anticipated to reach nearly $4 billion by 2031[10]. - Estimated unaudited revenue for the twelve months ended December 31, 2025, is projected at $4.3 billion[24]. Company Performance and Financials - The company generated approximately $43.0 million in revenue for 2025, representing a preliminary estimated growth of 251% compared to previous years[22]. - Gross margin improved significantly, with a jump of 2,858 basis points from 12.35% in 2023 to 40.63% in 2025[22]. - Gross profit margin for the nine months ended September 30, 2025, is reported at 48.1%[24]. - Operating income loss for the twelve months ended December 31, 2025, is estimated at $(20.9 million)[24]. - Net income loss for the twelve months ended December 31, 2025, is projected at $(0.14) per diluted share[24]. - Total assets as of September 30, 2025, amount to $21.1 billion[24]. - Current assets reported at $148.4 million as of September 30, 2025[24]. - Total stockholders' equity is noted at $11.7 billion[24]. - Current liabilities include long-term debt, with restricted cash of $6.0 million[24]. - Revenue for the nine months ended September 30, 2025, is reported at $76.1 million[24]. Product Development and Innovation - The company has established a comprehensive suite of surgical instruments supporting various procedures, including robotic cardiac surgery[4]. - The company has developed five new 5-millimeter surgical robotic instruments for clinical use across multiple specialties, including pediatric and cardiac surgery[14]. - The SSi Mantra Tele Surgeon Console enables telesurgery from various locations, with the first successful telesurgery completed in October 2025[17]. - The company aims to enhance its robotics platform through continuous innovation and new product development, targeting underserved markets and established hospitals[23]. Operational Highlights - The SSi Mantra installed base currently spans 10 countries with 168 systems installed and over 7,800 multi-specialty surgeries performed[4]. - SS Innovations has performed over 400 robotic cardiac surgeries and 120 telesurgeries with zero significant safety events reported[4]. - The installed base of the SSi Mantra system increased by 158% year-over-year, with completed procedures rising by 186%[19]. - The company has established a world-class R&D and manufacturing facility in India, with a production capacity of 20 systems per month as of October 31, 2025[18]. Strategic Goals and Market Expansion - The company aims to expand its presence in Europe and the United States while maintaining a strong foundational market in India[4]. - The company plans to expand its global presence, with 91% of revenue currently generated from India, and anticipates significant growth from international markets[20]. - SS Innovations is focused on enhancing access to surgical robotics in underserved regions, addressing the shortage of trained healthcare workers[8]. - The company is pursuing FDA approval for multi-specialty indications, with a 510(k) submission expected in Q4 2025 and market clearance anticipated in H1 2026[21]. Leadership and Ownership - SS Innovations has a strong insider ownership of 76.5%, indicating confidence from its leadership[5]. - The company has a distinguished leadership team with extensive experience in surgical robotics technology[6].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2026 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Number) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ...

Loan Agreement Details - The Borrower, AVITA Medical, Inc., has requested term loans from the Lenders under the Credit Agreement dated January 13, 2026[11]. - The Credit Agreement includes provisions for term loans and outlines the conditions for borrowing[13]. - The agreement specifies that the Administrative Agent is Perceptive Credit Holdings V, LP, which acts on behalf of the Lenders[11]. - The agreement includes various defined terms related to financial and operational metrics, such as "Acquisition" and "Asset Sale"[17][22]. - The document outlines the conditions precedent for the term loans, including compliance with financial covenants[6]. - The agreement includes provisions for the repayment of principal and interest, detailing the payment structure[33]. - The Borrower is required to maintain compliance with laws and agreements as part of the affirmative covenants[69]. - The agreement includes schedules that detail commitments, products, and regulatory approvals relevant to the Borrower's operations[7]. - The Borrower must comply with all applicable Laws, including federal, state, and local regulations[98]. - The term "Obligations" encompasses all amounts and liabilities owed by the Obligor to any Lender, including principal and interest on Term Loans, with specific fees and expenses outlined[112]. - The Borrower will utilize the proceeds of the Term Loans for general working capital purposes and to refinance existing Indebtedness[199]. - Each Lender agrees to provide its share of the Tranche A Term Loan on the Closing Date in a principal amount equal to such Lender's Tranche A Term Loan Commitment[186]. - The Borrower may make one borrowing under the Tranche A Term Loan Commitment on the Closing Date, with all amounts owed to be paid in full by the Maturity Date[188]. - The Borrower must deliver a fully executed Borrowing Notice to the Administrative Agent at least one Business Day in advance of the Closing Date[187]. - The Borrower may also make one borrowing under the Tranche B Term Loan Commitment, with similar terms regarding repayment by the Maturity Date[192]. - The Borrower must deliver a fully executed Borrowing Notice for the Tranche B Term Loan at least three Business Days in advance of the proposed Borrowing Date[191]. - The Closing Fee will be paid to the Administrative Agent on the Closing Date, in accordance with the Fee Letter[195]. - The Exit Fee will also be paid to the Administrative Agent as required, for distribution to each Lender[196]. - All Term Loans will be made and participations purchased by the Lenders simultaneously and proportionately to their respective Proportionate Shares[194]. - Any principal amount of the Term Loans that is repaid or prepaid may not be reborrowed[193]. Financial Performance - The company reported a total revenue of $60 million for the quarter, reflecting a 15% increase year-over-year[42]. - The company reported a significant increase in revenue, reaching $1.5 billion, representing a 25% year-over-year growth[1]. - The user base grew to 1.5 million active users, representing a 20% increase compared to the previous quarter[42]. - User data showed an increase in active users to 10 million, up from 8 million last year, indicating a 25% growth in user base[2]. - The company expects revenue guidance for the next quarter to be between $65 million and $70 million, indicating a potential growth of 8% to 17%[42]. - The company provided guidance for the next quarter, expecting revenue between $1.6 billion and $1.7 billion, which would represent a growth of 7% to 13%[3]. - The company reported a net profit margin of 12%, up from 10% in the previous quarter[42]. - The total assets of the company increased to $150 million, a 10% rise from the last fiscal year[42]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[8]. - Operating expenses were reported at $300 million, a 10% increase compared to last year, primarily due to increased marketing efforts[9]. Strategic Initiatives - New product launches are anticipated to contribute an additional $10 million in revenue over the next two quarters[42]. - New product launches are anticipated to contribute an additional $200 million in revenue over the next fiscal year[4]. - The company is investing $5 million in research and development for new technologies aimed at enhancing user experience[42]. - The company is investing $50 million in research and development for new technologies aimed at enhancing product features[5]. - Market expansion efforts are underway in Europe, with an expected increase in market share by 5% within the next year[42]. - Market expansion efforts include entering three new international markets, projected to increase overall market share by 5%[6]. - The company is exploring strategic acquisitions to bolster its product offerings and market presence[42]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $100 million allocated for potential deals[7]. - A new marketing strategy is set to increase brand awareness, targeting a 30% increase in customer engagement[42]. Compliance and Legal Matters - The Borrower is subject to various Health Care Laws related to the manufacturing, sale, and distribution of health care products and services[84]. - Indebtedness includes all obligations for borrowed money, bonds, notes, and other financial instruments, with a specific focus on obligations exceeding $500,000[107]. - Material Indebtedness is defined as any Indebtedness of any Obligor with an outstanding principal amount exceeding $500,000[107]. - The definition of Investment includes acquisitions of equity interests, loans, and guarantees, with specific exclusions for ordinary course trade receivables[96]. - The term "Material Adverse Change" refers to significant negative impacts on the business, financial condition, or operations of the Obligors[105]. - The Loan Exposure for any Lender is defined as the outstanding principal amount of that Lender's portion of the Term Loans[101]. - The Maturity Date is the earlier of the Stated Maturity Date or the date when Term Loans are accelerated[109]. - The definition of Indemnified Taxes includes taxes imposed on payments made by or on account of any Obligation[88]. - "Permitted Acquisition" allows for acquisitions by the Obligor or its subsidiaries, provided they comply with various conditions, including no existing defaults and prior notice to the Administrative Agent[123]. - "Product Development and Commercialization Activities" includes a range of activities aimed at commercially exploiting a product, such as research, development, and marketing[138]. - "Regulatory Approvals" are necessary for the manufacturing and commercialization of products, including all relevant authorizations from governmental authorities[145]. - "Permitted Cash Equivalent Investments" include marketable obligations and commercial paper with specific maturity and rating criteria[125]. - "Prohibited Payment" refers to any illegal payments made to government officials or related entities, which are strictly forbidden under law[139]. - "Obligor Intellectual Property" includes all intellectual property owned or licensed by the Obligor, which is critical for its operations[113]. - "Product Assets" consist of all rights and interests related to a product, including intellectual property and regulatory approvals necessary for its commercialization[136]. - "Other Taxes" refers to various taxes arising from payments made under loan documents, excluding connection taxes[118]. - "Permitted Indebtedness" includes any debt that is allowed under specific sections of the agreement, ensuring compliance with financial covenants[126]. - The Borrower must provide a detailed notice of any Accounting Change to the Administrative Agent[178]. - All financial calculations for compliance must adjust for any acquisitions or dispositions of assets[179]. - The Borrower is required to negotiate amendments to provisions affected by any Accounting Change[178]. - The Borrower must provide a written reconciliation of calculations before and after any Accounting Change[178]. - The term "Solvent" is defined based on the fair value of property exceeding total liabilities[158]. - The term "Unrestricted Cash" refers to unencumbered cash held in a Controlled Account[174]. - The term "Sanctions" includes economic or financial sanctions imposed by Governmental Authorities[151].

Financial Results - Ichor Holdings, Ltd. announced preliminary financial results for Q4 2025, which are subject to change and not yet audited [7]. - The company has not yet filed its annual report on Form 10-K for the fiscal year 2025, indicating ongoing financial review processes [8]. - Preliminary results are based on management estimates and may materially differ from actual results once finalized [8]. Compliance and Disclosure - The company utilizes its website's "Investors" section for disclosing material non-public information, complying with Regulation FD [10].

Financial Results Announcement - Red Cat Holdings, Inc. announced preliminary unaudited revenue results for Q4 and full year 2025, with specific figures to be disclosed upon completion of the annual audit[4]. - The preliminary results are subject to adjustments and do not represent a comprehensive statement of the Company's financial performance for the period[5]. - The Company has not yet filed its annual report on Form 10-K for the fiscal year 2025, indicating that final results may differ from preliminary estimates[5].